"Imidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
| Descriptor ID |
D007093
|
| MeSH Number(s) |
D03.383.129.308
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Imidazoles".
Below are MeSH descriptors whose meaning is more specific than "Imidazoles".
This graph shows the total number of publications written about "Imidazoles" by people in this website by year, and whether "Imidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 2 | 3 | 5 |
| 2016 | 2 | 1 | 3 |
| 2017 | 40 | 26 | 66 |
| 2018 | 35 | 24 | 59 |
| 2019 | 6 | 5 | 11 |
| 2020 | 2 | 2 | 4 |
| 2021 | 5 | 5 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Imidazoles" by people in Profiles.
-
Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19. Clin Transl Sci. 2021 11; 14(6):2556-2565.
-
Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. J Med Virol. 2021 12; 93(12):6750-6759.
-
Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease. Sci Rep. 2021 08 19; 11(1):16843.
-
A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection. Mol Syst Biol. 2021 08; 17(8):e10239.
-
The interaction of the severe acute respiratory syndrome coronavirus 2 spike protein with drug-inhibited angiotensin converting enzyme 2 studied by molecular dynamics simulation. J Hypertens. 2021 08 01; 39(8):1705-1716.
-
Characterization of the Modulatory Effect of Hydroxychloroquine on ACE2 Activity: New Insights in relation to COVID-19. Biomed Res Int. 2021; 2021:6614000.
-
Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther. 2022 02; 20(2):291-295.
-
Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease. Proteins. 2021 11; 89(11):1425-1441.
-
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021 Oct; 54(5):767-775.
-
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. J Antimicrob Chemother. 2021 06 18; 76(7):1874-1885.